TY - JOUR
T1 - SOS1 is the second most common Noonan gene but plays no major role in cardio-facio-cutaneous syndrome
AU - Zenker, Martin
AU - Horn, Denise
AU - Wieczorek, Dagmar
AU - Allanson, Judith
AU - Pauli, Silke
AU - Van Der Burgt, Ineke
AU - Doerr, Helmuth Guenther
AU - Gaspar, Harald
AU - Hofbeck, Michael
AU - Gillessen-Kaesbach, Gabriele
AU - Koch, Andreas
AU - Meinecke, Peter
AU - Mundlos, Stefan
AU - Nowka, Anja
AU - Rauch, Anita
AU - Reif, Silke
AU - Von Schnakenburg, Christian
AU - Seidel, Heide
AU - Wehner, Lars Erik
AU - Zweier, Christiane
AU - Bauhuber, Susanne
AU - Matejas, Verena
AU - Kratz, Christian P.
AU - Thomas, Christoph
AU - Kutsche, Kerstin
PY - 2007/10
Y1 - 2007/10
N2 - Background: Heterozygous gain-of-function mutations in various genes encoding proteins of the Ras-MAPK signalling cascade have been identified as the genetic basis of Noonan syndrome (NS) and cardio-facio-cutaneous syndrome (CFCS). Mutations of SOS1, the gene encoding a guanine nucleotide exchange factor for Ras, have been the most recent discoveries in patients with NS, but mis gene has not been studied in patients with CFCS. Methods and results: We investigated SOS1 in a large cohort of patients with disorders of the NS-CFCS spectrum, who had previously tested negative for mutations in PTPN11, KRAS, BRAF, MEK1 and MEK2. Missense mutations of SOS1 were discovered in 28% of patients with NS. In contrast, none of the patients classified as having CFCS was found to carry a pathogenic sequence change in this gene. Conclusion: We have confirmed SOS1 as the second major gene for NS. Patients carrying mutations in this gene have a distinctive phenotype with frequent ectodermal anomalies such as keratosis pilaris and curly hair. However, the clinical picture associated with SOS1 mutations is different from that of CFCS. These findings corroborate that, despite being caused by gain-of-function mutations in molecules belonging to the same pathway, NS and CFCS scarcely overlap genotypically.
AB - Background: Heterozygous gain-of-function mutations in various genes encoding proteins of the Ras-MAPK signalling cascade have been identified as the genetic basis of Noonan syndrome (NS) and cardio-facio-cutaneous syndrome (CFCS). Mutations of SOS1, the gene encoding a guanine nucleotide exchange factor for Ras, have been the most recent discoveries in patients with NS, but mis gene has not been studied in patients with CFCS. Methods and results: We investigated SOS1 in a large cohort of patients with disorders of the NS-CFCS spectrum, who had previously tested negative for mutations in PTPN11, KRAS, BRAF, MEK1 and MEK2. Missense mutations of SOS1 were discovered in 28% of patients with NS. In contrast, none of the patients classified as having CFCS was found to carry a pathogenic sequence change in this gene. Conclusion: We have confirmed SOS1 as the second major gene for NS. Patients carrying mutations in this gene have a distinctive phenotype with frequent ectodermal anomalies such as keratosis pilaris and curly hair. However, the clinical picture associated with SOS1 mutations is different from that of CFCS. These findings corroborate that, despite being caused by gain-of-function mutations in molecules belonging to the same pathway, NS and CFCS scarcely overlap genotypically.
UR - http://www.scopus.com/inward/record.url?scp=35348871857&partnerID=8YFLogxK
U2 - 10.1136/jmg.2007.051276
DO - 10.1136/jmg.2007.051276
M3 - Journal articles
C2 - 17586837
AN - SCOPUS:35348871857
SN - 0022-2593
VL - 44
SP - 651
EP - 656
JO - Journal of Medical Genetics
JF - Journal of Medical Genetics
IS - 10
ER -